A gene called FOXJ1 may drive resistance to taxane chemotherapy during treatment for advanced prostate cancer, according to a new study led by investigators at Weill Cornell Medicine and Beth Israel ...

More than 400 cartons of Nilotinib capsules were voluntarily recalled by Cipla USA after failing manufacturing specifications ...

Cipla USA, a subsidiary of the Indian drugmaker, is recalling over 400 cartons of generic anti-cancer drug Nilotinib due to a manufacturing issue. The recall is classified as Class III by the USFDA, ...

Cipla USA is recalling over 400 cartons of its anti-cancer drug Nilotinib Capsules. The recall is due to a manufacturing issue where the capsules failed to meet specifications. This is a voluntary ...

Merck & Co., Inc. (NYSE:MRK) has been on a strong recovery run, gaining 23% over the past year and 8% year-to-date, though ...

Cipla USA is voluntarily recalling over 400 cartons of its anti-cancer drug, Nilotinib Capsules, due to a manufacturing issue.

A US-based subsidiary of Cipla has recalled more than 400 cartons of a generic anti-cancer medication from the American market after a manufacturing-related issue was detected, according to the US ...

The treatment landscape for breast cancer is shifting rapidly, driven by the rise of antibody-drug conjugates (ADCs), a class of treatments that are designed to deliver potent che ...

Explore the latest colorectal cancer treatment advances, from precision oncology and immunotherapy to ADCs, bispecifics, and ...

The Food and Drug Administration on Tuesday approved a generic medication for a rare brain disorder, while walking back suggestions by President Donald Trump and other administration officials that ...